Talc pleurodesis has been used for more than 50 years in both the United States and in Europe, and it has proven to be safe and effective in patients with malignant pleural effusions as well as recurrent pneumothorax. In inserted through the pleural trocars used during thoracoscopy. Use of this spray canister allows practitioners to avoid complex handling and sterilization procedures required for bulk talc powder. (Chest 1994; 106:1776-80) MPE=malignant pleural effusions
Talc pleurodesis has been used for more than 50 by gamma radiation and marketed in a sterile peel pack in which are also enclosed 15-and 25-cm hollow plastic delivery catheters. The propellant is dichlorodifluoromethane.
Prior to pleurodesis, the sterile talc canister and nozzles should be removed from the sterile packaging, after which the protective cap on the canister may be removed and the canister shaken. The nozzle and delivery catheter are then securely attached to the canister. Usage of the shorter 15-cm catheter is recommended for application through pleural trocars or at the thoracotomy site. The distal extremity should not be in close proximity to lung parenchyma. It is somewhat sharp and may cause parenchymal damage. In addition, the talc is delivered under pressure. Although no pressure-related damage has yet been seen, it is a potential danger of pressurized talc spray administration. While firmly holding the nozzle and delivery catheter together in one hand, pressure is applied to the nozzle on the canister. The distal extremity of the delivery catheter should be pointed in several different directions to ensure equal and extensive delivery over all pleural surfaces. The talc canister is kept vertical to maximize distribution. In case of limited talc pleurodesis, talc is applied only to the area of interest. During talc delivery, the canister becomes cold, signaling near total talc evacuation. If talc is delivered through a pleural trocar during thoracoscopy, care should be taken to keep the distal extremity of the delivery catheter about 0.5 cm beyond the tip of the pleural cannula. Otherwise, talc will adhere to the sides of the cannula, and intrapleural distributions will be unsatisfactory. After application, the talc canister and delivery catheters should be discarded.
Preliminary Clinical Experience
We have used this device in 12 patients with MPE and in 9 patients with spontaneous pneumothoraxes (in addition to bleb or bulla resection). Pleurodesis was successful at 90 d (defined as absence of symptoms attributable to effusions, clinically insignificant increase of pleural effusion evidenced on chest x-ray film compared with baseline films, and requiring no further thoracentesis) in 11 of 12 patients and in all patients with pneumothorax (the follow-up was 1 year). No complications of talc administration occurred, although about 30% of patients had lowgrade temperatures after thoracoscopy. A prospective study comparing talc pleurodesis using this device and routine talc powder administration using a standard pneumatic atomizer (Richard Wolf Co.) is underway. Possible Benefits and Pitfalls Overall, this disposable canister is effective and practical. Complex in-hospital sterilization and handling procedures of bulk talc powder are avoided, and talc administration is simple, rapid, and clean. The canister is expensive, however, when compared with other talc preparations. For example, at University of California, San Diego, Medical Center, routine talc preparation, including purchase, sterilization, packaging, and handling, costs only $4.00. Another drawback of the canister is the inability to quantify talc administration. For example, we use the entire contents of a canister for patients with MPE and extensive neoplastic parietal pleura involvement, but we use only a few spray applications for limited pleurodesis in patients with benign disease or pneumothorax. Unfortunately, there is no way of quantifying the amount of talc delivered is less than the entire contents is used. This is quite different from the way standard talc powder is packaged in our institutions (in sterile plastic test tubes containing either 1.2 or 2.5 g of sterile talc powder).
Some minor pitfalls relate to the delivery catheters. Their tips are too sharp and could tear lung parenchyma. We have easily done this in experimental animal models. Also, talc tends to clump if the delivery catheter is held too close to the lung or to the chest wall parietal pleura. We believe that thoracoscopic administration of talc with the canister through a single point of entry is more difficult than through two points of entry, where the delivery catheter's position can be easily verified thoracoscopically. The delivery catheter also may detach from the nozzle as pressure is applied. For this reason, the canister, nozzle, and catheter should be held firmly during application. In regard to previous suggestions of aerosolized talc delivery through an indwelling chest tube, we find this totally unsatisfactory. Talc clumps CHEST / 106 / 6 / DECEMBER, 1994 1777 up inside the chest tube, even when the longer 25-cm delivery catheter is used. Therefore, we do not believe that aerosolized talc delivery through an indwelling chest tube can replace talc slurry administration.
DISCUSSION
Talc pleurodesis was first suggested in 1935 by Bethune,8 a Canadian surgeon who investigated methods of achieving adherence of lung parenchyma to the chest wall prior to performing lobectomy. In this study, Bethune actually credits a deceased Canadian physician, R. U. Harwood, for suggesting the use of commercial talc for this technique because of the known fibrogenic properties of silicate powders. Bethune also describes the first thoracoscopic administration of talc powder using a specially designed "return-air" blower made by the Pilling Company. Subsequently, thoracoscopic talc poudrage (poudrage, which is French for powdering, consists of spraying sterile talc powder over the visceral and parietal pleura surfaces) was used for pleurodesis in patients with tuberculosis as well as in patients with spontaneous pneumothorax,9,10 although several surgeons later preferred talc administration via thoracotomy, even in patients with malignant pleural effusions.11"'5 In 1958, Chambers,'6 a thoracic surgeon from San Diego, revived the technique of talc slurry pleurodesis (by talc slurry, one usually means that sterile talc powder is diluted in 50 to 200 mL of normal saline solution and instilled via pleural trocar or chest tube), reporting an 85% success rate after instillation through an indwelling chest tube. Similar results were reported in 1967 by Jones17 using thoracoscopic application of talc slurry, and in 1976 by Adler and England and by Leophonte et a137 in France show that pure talc (containing no asbestos) is not carcinogenic. Both the European and American Pharmacopoeia, therefore, have instituted strict guidelines for medical-grade and cosmetic-grade talc composition,38-40 not only addressing requirements for asbestos-free talc, but also limiting its contamination with bacteria or other minerals. Although further research is required in this area, current evidence suggests that fears of asbesto-free, pure talc-induced neoplasms are unfounded. To our knowledge, no cases of neoplasm caused by intrapleural administration of sterile, asbestos-free talc have been reported.
Many studies have demonstrated that talc pleurodesis is a safe and effective means of achieving apposition of the pleural surfaces in patients with MPE.
Success rates are reportedly greater than 85%. 6, 22, 4147 In animal experiments as early as in 1941, Lelourd41 showed that pleurodesis was achieved by the 7th day after talc administration. In a recent canine study, Bresticker et a17 reported that pleural symphysis from talc was comparable to that obtained by mechanical abrasion. Mathlouti et a149 showed that talc caused an inflammatory reaction confined to the pleural surfaces, confirming previous work done by Frankel et al. 50 Controversy subsists, however, regarding the ideal method of administration, and it is unclear whether poudrage has any advantages over slurry. Boutin et success in 42 patients, and Aelony et al44 showed success in 23 of 28 (82%) patients. Hartman et a16 compared the use of insufflation of talc under thoracoscopic guidance with control populations who had received either tetracycline or bleomycin pleurodesis, reporting a 95% success rate of talc at 90 days compared with 70%o for bleomycin and 47% for tetracycline. Poudrage may be more effective than simple administration of talc slurry through a previously placed chest tube because adhesions and loculated fluid collections seen during thoracoscopy can be removed prior to pleurodesis. Additional, prospective, multi-armed randomized protocols and animate laboratory research are necessary, however, to further define indications for the selected techniques of talc administration.
In contrast to many favorable clinical reports of talc pleurodesis, there are reports of immediate adverse effects of intrapleural talc administration and those suggesting potential restrictive ventilatory impairment years after talc pleurodesis for recurrent pneumothorax.52 Roujeau whereas, at the University of California, San Diego, Medical Center, medical-grade asbestos-free US Pharmacopoeia-approved talc powder is purchased in bulk form, packaged in unit doses, and sterilized using a combination of ethylene oxide and dry heat. While some hospitals willingly share their handling guidelines, others refuse to do so categorically. The availability of a sterile, asbestos-free talc spray canister could facilitate talc acquisition and provide an alternative to institutionally prepared talc for pleurodesis.
